PETALUMA, Calif., Sept. 11, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a commercial healthcare company that designs, produces and markets innovative, safe and effective healthcare products, today announced the issuance of new U.S. patent for the use of Microcyn® Technology in the prevention and treatment of peritonitis. In this application, Microcyn® can be delivered to the peritoneal cavity intra-operatively, laproscopically or transabdominally; and can be administered to peritoneal tissue already affected by peritonitis or tissue at risk of developing this infection.
Hoji Alimi, founder and president of Oculus said: "The issuance of this U.S. patent for prevention and treatment of peritonitis strategically dovetails with our longer-term plan of securing drug approval from the FDA for the surgical use of Microcyn Technology. This is a significant market in which current standards simply don't provide patients with optimum protection. We believe Microcyn Technology will help reduce the incidence of infection, such as that associated with peritonitis and other abdominal procedures, and as such, will reduce healthcare costs and improve patient outcomes."
The latest-issued patent joins an intellectual property estate (either owned or licensed to Oculus) that now includes 17 issued patents (6 in the U.S. and 2 in the E.U.) as well as 16 U.S. and 101 foreign pending applications directed to chemical compositions, apparatuses, methods of manufacturing and therapeutic uses.About Peritonitis Peritonitis is an inflammation of the internal lining of the abdominal cavity. The most common causes of peritonitis are bacterial infection and chemical irritation. Bacterial peritonitis is usually secondary to bacterial penetration through an abdominal organ as occurs with disorders such as appendicitis, acute cholecystitis, peptic ulcers, diverticulitis, bowel obstruction, pancreatitis, mesenteric thrombosis, pelvic inflammatory disease, tumor or penetrating trauma, or combinations thereof. The methods currently used for treating or preventing peritonitis are limited. In some cases, chemical peritonitis can respond to irrigation of the abdominal cavity. The use of multiple re-explorations and intra-operative lavage with large amounts of sterile saline solution has been recommended to decrease the risk of post-operative peritoneal infection, peritonitis and adhesions. However, there is still a significant risk of developing peritonitis and adhesions despite the use of repeated lavages with sterile saline. Various topical antimicrobials have also been tested but none has been widely accepted for source control due to either, lack of efficacy or serious side effects (i.e. sclerosing peritonitis).